{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:08:13Z","timestamp":1778882893040,"version":"3.51.4"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.schres.2025.11.013","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:20:08Z","timestamp":1763684408000},"page":"54-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cannabis use and cardiometabolic risk in schizophrenia"],"prefix":"10.1016","volume":"287","author":[{"given":"Jai","family":"Paris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Laurendi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Arnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherrie","family":"Galletly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2025.11.013_bb0005","article-title":"The impact of THC and CBD in schizophrenia: a systematic review","volume":"12","author":"Ahmed","year":"2021","journal-title":"Front. Psychol."},{"key":"10.1016\/j.schres.2025.11.013_bb0010","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2025.11.013_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15479-x","article-title":"Risk factors for metabolic syndrome in individuals with recent-onset psychosis at disease onset and after 1-year follow-up","volume":"12","author":"Alonso","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.schres.2025.11.013_bb0020","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(87)92620-1","article-title":"Cannabis and schizophrenia. A longitudinal study of Swedish conscripts","volume":"2","author":"Andr\u00e9asson","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2025.11.013_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102199","article-title":"Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals","volume":"64","author":"Argote","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.schres.2025.11.013_bb0030","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nn.2494","article-title":"Bimodal control of stimulated food intake by the endocannabinoid system","volume":"13","author":"Bellocchio","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.schres.2025.11.013_bb0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00406-002-0366-5","article-title":"Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes","volume":"252","author":"Bersani","year":"2002","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"12","key":"10.1016\/j.schres.2025.11.013_bb0040","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","article-title":"Cannabidiol: pharmacology and therapeutic targets","volume":"238","author":"Britch","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2025.11.013_bb0050","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/0269881116631652","article-title":"Cannabis use in people with severe mental illness: the association with physical and mental health--a cohort study. A pharmacotherapy monitoring and outcome survey study","author":"Bruins","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2025.11.013_bb0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/can.2023.0032","article-title":"Assessing Cannabis use in people with psychosis","volume":"9","author":"Chesney","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.schres.2025.11.013_bb0065","first-page":"1001","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","volume":"11","author":"Chong","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.schres.2025.11.013_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107477","article-title":"The therapeutic potential of second and third generation CB(1)R antagonists","volume":"208","author":"Cinar","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.schres.2025.11.013_bb0075","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20994","article-title":"Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors","volume":"21","author":"Correll","year":"2022","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2025.11.013_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006162.pub2","article-title":"Rimonabant for overweight or obesity","volume":"2006","author":"Curioni","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2025.11.013_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111263","article-title":"The prevalence of cannabis use disorders in people who use medicinal cannabis: a systematic review and meta-analysis","volume":"257","author":"Dawson","year":"2024","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.schres.2025.11.013_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpr.2025.102581","article-title":"The differential effects of medicinal cannabis on mental health: a systematic review","volume":"118","author":"De Bode","year":"2025","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.schres.2025.11.013_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176821","article-title":"Investigating Cannabidiol\u2019s potential as a supplementary treatment for schizophrenia: a narrative review","volume":"979","author":"Denis V\u00f6lker","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.schres.2025.11.013_bb9000","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.3390\/ph3103101","article-title":"Endocannabinoids and Schizophrenia","volume":"10","author":"Desfoss\u00e9s","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.schres.2025.11.013_bb0100","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1192\/bjp.bp.109.064220","article-title":"High-potency cannabis and the risk of psychosis","volume":"195","author":"Di Forti","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2025.11.013_bb0105","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.biopsych.2012.06.020","article-title":"Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users","volume":"72","author":"Di Forti","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","article-title":"The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study","volume":"6","author":"Di Forti","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"11(2)","key":"10.1016\/j.schres.2025.11.013_bb0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/biomedicines11020306","article-title":"Role of the endocannabinoid system in metabolic control processes and in the pathogenesis of metabolic syndrome: an update","volume":"21","author":"D\u00f6rnyei","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.schres.2025.11.013_bb0120","first-page":"603","article-title":"A comprehensive review of Cannabis potency in the United States in the last decade","author":"ElSohly","year":"2021","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"10.1016\/j.schres.2025.11.013_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1442522","article-title":"A 10-year trend in cannabis potency (2013\u22122022) in different geographical regions of the United States of America","volume":"12","author":"ElSohly","year":"2024","journal-title":"Front. Public Health"},{"key":"10.1016\/j.schres.2025.11.013_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41398-020-0756-3","article-title":"Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study","volume":"10","author":"Farokhnia","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0135","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1176\/appi.ajp.2010.09020189","article-title":"Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization","volume":"167","author":"Foti","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/mpr.1813","article-title":"Psychotic disorders hospitalizations associated with cannabis abuse or dependence: a nationwide big data analysis","volume":"29","author":"Gon\u00e7alves-Pinho","year":"2020","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.schres.2025.11.013_bb0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s13679-025-00633-z","article-title":"Cannabis, weight, and weight-related behaviors","volume":"14","author":"Goodpaster","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.schres.2025.11.013_bb0150","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/0004867414553950","article-title":"Inadequate fruit and vegetable intake in people with psychosis","volume":"48","author":"Hahn","year":"2014","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2025.11.013_bb0160","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1017\/S0033291724000758","article-title":"Use of antipsychotic medication, benzodiazepines, and psychiatric hospitalization in cannabis-related versus cannabis-unrelated schizophrenia - a nationwide, register-based cohort study","volume":"54","author":"Hjorthoj","year":"2024","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2025.11.013_bb0165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.forsciint.2006.08.005","article-title":"Cannabinoid concentrations in hair from documented cannabis users","volume":"169","author":"Huestis","year":"2007","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.schres.2025.11.013_bb0175","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1038\/s41598-024-54367-4","article-title":"Metabolic syndrome: a population-based study of prevalence and risk factors","volume":"14","author":"Jamali","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.schres.2025.11.013_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1386263","article-title":"Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen","volume":"15","author":"Johnson","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.736822","article-title":"Cannabidiol cigarettes as adjunctive treatment for psychotic disorders - a randomized, open-label pilot-study","volume":"12","author":"K\u00f6ck","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2025.11.013_bb0190","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/aje\/kwr200","article-title":"Obesity and cannabis use: results from 2 representative national surveys","volume":"174","author":"Le Strat","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.schres.2025.11.013_bb0200","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1038\/s41598-025-86385-1","article-title":"Changes of metabolic syndrome status alter the risks of cardiovascular diseases, stroke and all cause mortality","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.schres.2025.11.013_bb0205","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1176\/appi.ajp.2011.11010039","article-title":"The NIMH-CATIE schizophrenia study: what did we learn?","volume":"168","author":"Lieberman","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0210","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2\u20133","key":"10.1016\/j.schres.2025.11.013_bb0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2016.08.014","article-title":"Cannabis and a lower BMI in psychosis: what is the role of AKT1?","volume":"176","author":"Liemburg","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.11.013_bb0225","first-page":"607","article-title":"Review of the endocannabinoid system","volume":"6","author":"Lu","year":"2021","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"10.1016\/j.schres.2025.11.013_bb0230","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/10398562231222818","article-title":"Impacts of medicinal cannabis on an early psychosis service","volume":"2","author":"Lupke","year":"2024","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0240","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s13311-015-0382-6","article-title":"Cannabinoids and schizophrenia: risks and therapeutic potential","volume":"12","author":"Manseau","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.schres.2025.11.013_bb0245","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2025.13479","article-title":"Metabolic syndrome in patients with schizophrenia: underlying mechanisms and therapeutic approaches (review)","volume":"31","author":"Manta","year":"2025","journal-title":"Mol. Med. Rep."},{"issue":"7,Suppl7","key":"10.1016\/j.schres.2025.11.013_bb0250","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1017\/S1092852900026626","article-title":"Introduction: an overview of the clinical antipsychotic trials of intervention effectiveness (CATIE) study","volume":"11","author":"Mcevoy","year":"2006","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2025.11.013_bb0255","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0260","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/jamapsychiatry.2016.0637","article-title":"Associations between Cannabis use and physical health problems in early midlife: a longitudinal comparison of persistent Cannabis vs tobacco users","volume":"73","author":"Meier","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0265","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/PSY.0000000000000665","article-title":"Associations between Cannabis use and cardiometabolic risk factors: a longitudinal study of men","volume":"81","author":"Meier","year":"2019","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.schres.2025.11.013_bb0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3934\/Neuroscience.2025003","article-title":"The role of tetrahydrocannabivarin (THCV) in metabolic disorders: a promising cannabinoid for diabetes and weight management","volume":"12","author":"Mendoza","year":"2025","journal-title":"AIMS Neurosci"},{"key":"10.1016\/j.schres.2025.11.013_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114387","article-title":"Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States: Submit to: Psychiatry Research","volume":"308","author":"Moran","year":"2022","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2025.11.013_bb0285","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57868","article-title":"Changes in incident schizophrenia diagnoses associated with Cannabis use disorder after Cannabis legalization","volume":"8","author":"Myran","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.schres.2025.11.013_bb0290","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s42238-023-00186-9","article-title":"The therapeutic potential of purified cannabidiol","volume":"5","author":"O\u2019Sullivan","year":"2023","journal-title":"J. Cannabis Res."},{"issue":"1","key":"10.1016\/j.schres.2025.11.013_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2023.2166414","article-title":"On the challenges of hair testing to detect underreported substance use in research settings","volume":"49","author":"Palamar","year":"2023","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.schres.2025.11.013_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020243","article-title":"The expanded endocannabinoid system contributes to metabolic and body mass shifts in first-episode schizophrenia: a 5-year follow-up study","volume":"10","author":"Parksepp","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.schres.2025.11.013_bb0305","article-title":"The association between Cannabis use and schizophrenia: causative or curative? A systematic review","volume":"12","author":"Patel","year":"2020","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.schres.2025.11.013_bb0310","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.amjmed.2013.03.002","article-title":"The impact of marijuana use on glucose, insulin, and insulin resistance among US adults","volume":"126","author":"Penner","year":"2013","journal-title":"Am. J. Med."},{"key":"10.1016\/j.schres.2025.11.013_bb0315","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40261-022-01205-y","article-title":"Effects of cannabidiol on appetite and body weight: a systematic review","volume":"11","author":"Pinto","year":"2022","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.schres.2025.11.013_bb0320","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41537-025-00642-w","article-title":"Prevalence of cardiovascular risk factors and disease in patients with schizophrenia: baseline results from a prospective cohort study with long-term clinical follow-up","volume":"11","author":"Polcwiartek","year":"2025","journal-title":"Schizophrenia (Heidelb)"},{"key":"10.1016\/j.schres.2025.11.013_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/biom15030368","article-title":"Does cannabis use contribute to schizophrenia? A causation analysis based on epidemiological evidence","volume":"15","author":"Pourebrahim","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.schres.2025.11.013_bb0330","article-title":"Does cannabis affect cognitive functioning in patients with schizophrenia?","volume":"36","author":"Rachid","year":"2024","journal-title":"Schizophr. Res. Cogn."},{"key":"10.1016\/j.schres.2025.11.013_bb0335","doi-asserted-by":"crossref","DOI":"10.1097\/j.pbj.0000000000000101","article-title":"Metabolic syndrome in type 2 diabetic patients: a review of current evidence","volume":"5","author":"Regufe","year":"2020","journal-title":"Porto Biomed J"},{"key":"10.1016\/j.schres.2025.11.013_bb0340","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neubiorev.2020.07.007","article-title":"Cannabis, nicotine and the negative symptoms of schizophrenia: systematic review and meta-analysis of observational studies","volume":"116","author":"Sabe","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.schres.2025.11.013_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1343427","article-title":"Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review","volume":"15","author":"Saccaro","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0350","first-page":"973","article-title":"Global prevalence of metabolic syndrome in schizophrenia patients: a systematic review and meta-analysis","volume":"45","author":"Salari","year":"2024","journal-title":"J. Prev. Dent. (2022)"},{"key":"10.1016\/j.schres.2025.11.013_bb0355","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2018.02.050","article-title":"Effects of cannabis use on body mass, fasting glucose and lipids during the first 12\u00a0months of treatment in schizophrenia spectrum disorders","volume":"199","author":"Scheffler","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.11.013_bb0360","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13065-019-0627-2","article-title":"A review of bioanalytical techniques for evaluation of cannabis (marijuana, weed, hashish) in human hair","volume":"13","author":"Shah","year":"2019","journal-title":"BMC Chem"},{"issue":"4","key":"10.1016\/j.schres.2025.11.013_bb0365","first-page":"149","article-title":"Chemistry, metabolism, and toxicology of cannabis: clinical implications","volume":"7","author":"Sharma","year":"2012","journal-title":"Iran. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0370","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3502","article-title":"Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors","volume":"38","author":"Silveira Rossi","year":"2022","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.schres.2025.11.013_bb0375","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/eip.13030","article-title":"Cannabis use and metabolic syndrome among clients with first episode psychosis","volume":"15","author":"Stiles","year":"2021","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.schres.2025.11.013_bb0380","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2025.11.013_bb0385","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/dar.12412","article-title":"Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users","volume":"36","author":"Taylor","year":"2017","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.schres.2025.11.013_bb0390","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1038\/s41598-022-22841-6","article-title":"Association between cannabis use and blood pressure levels according to comorbidities and socioeconomic status","volume":"13","author":"Vall\u00e9e","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.schres.2025.11.013_bb0395","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0269881118822173","article-title":"Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: results from a three-year longitudinal study","author":"Vazquez-Bourgon","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2025.11.013_bb0400","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.amjmed.2015.10.019","article-title":"Metabolic syndrome among marijuana users in the United States: an analysis of National Health and Nutrition Examination Survey Data","volume":"129","author":"Vidot","year":"2016","journal-title":"Am. J. Med."},{"issue":"25","key":"10.1016\/j.schres.2025.11.013_bb0405","first-page":"597","article-title":"Prevalence of cannabis use around the world: a systematic review and meta-analysis, 2000-2024","volume":"6","author":"Wang","year":"2024","journal-title":"China CDC Wkly."},{"key":"10.1016\/j.schres.2025.11.013_bb0410","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1017\/S0033291715002883","article-title":"Metabolic syndrome in people with a psychotic illness: is cannabis protective?","volume":"46","author":"Waterreus","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2025.11.013_bb0415","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.drugalcdep.2018.11.006","article-title":"Sex differences in the cardiometabolic health of cannabis users with a psychotic illness","volume":"194","author":"Waterreus","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.schres.2025.11.013_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12144620","article-title":"The use of cannabidiol in metabolic syndrome-an opportunity to improve the patient\u2019s health or much ado about nothing?","volume":"12","author":"Wici\u0144ski","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.schres.2025.11.013_bb0425","series-title":"IBM Corp. Version 29.0.2.0 ed","author":"Windows","year":"2023"},{"key":"10.1016\/j.schres.2025.11.013_bb0430","series-title":"Obesity: Preventing and Managing the Global Epidemic","author":"World Health Organization (WHO)","year":"2000"},{"issue":"6","key":"10.1016\/j.schres.2025.11.013_bb0435","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/schbul\/sbac095","article-title":"Influences on the genetic relationship between Cannabis use and schizophrenia: the role of the externalizing spectrum","volume":"48","author":"Wormington","year":"2022","journal-title":"Schizophr. Bull."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425004037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425004037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:33:09Z","timestamp":1766493189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996425004037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":81,"alternative-id":["S0920996425004037"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2025.11.013","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabis use and cardiometabolic risk in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2025.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}